| 41/237 | US=11 / Cab/Pesc Kies MS. Principles of chemotherapy. In: Neligan PC, Wei FC. Microsurgical reconstruction of the Head and Neck. St Louis: QMP, 2010. p. 53-76. CANCER DE CABECA E PESCOCO; QUIMIOTERAPIA; CARCINOMA DE CELULAS ESCAMOSAS; TERAPIA COMBINADA; QUIMIOIRRADIACAO; QUIMIOTERAPIA DE INDUCAO; QUMIOTERAPIA SISTEMICA; TERAPIA-ALVO |
| 42/237 | US=5 / Gastro Kim E, Zalupski MM. Systemic therapies for advanced hepatocellular carcinoma: review of current status of chemotherapy for the treatment of hepatocellular carcinoma. In: Hussain HK, Francis IR. Primary carcinomas of the liver. New York: Cambridge University Press, 2010. p. 113-21. (Contemporary issues in cancer imaging) ISBN 978-0-524-51951-9. CANCER DE FIGADO; CARCINOMA HEPATOCELULAR; CARCINOMA HEPATOCELULAR. TRATAMENTO NAO-CIRURGICO; CARCINOMA HEPATOCELULAR. ESTAGIO AVANCADO; QUIMIOTERAPIA; AGENTES CITOTOXICOS; BIOTERAPIA; TERAPIA-ALVO |
| 43/237 | US=5 / Gastro Khan GN, Zalupski MM. Treatment of cholangiocarcinoma: non-surgical treatment - systemic therapy. In: Hussain HK, Francis IR. Primary carcinomas of the liver. New York: Cambridge University Press, 2010. p. 206-213. (Contemporary issues in cancer imaging) ISBN 978-0-524-51951-9. CANCER DE FIGADO; CARCINOMA HEPATOCELULAR; COLANGIOCARCINOMA; COLANGIOCARCINOMA. TRATAMENTO NAO-CIRURGICO; TERAPIA SISTEMICA; QUIMIOTERAPIA; FLUOROPIRIMIDINA; GEMCITABINA; TERAPIA-ALVO |
| 44/237 | US=25 / Mama Balsega J. Newer targeted therapy in breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the breast. 4ªed. Philadelphia: Lippincott Williams & Wilkins, 2010. p. 971-8. ISBN 978-0-7817-9117-5. |
| 45/237 | US=9 / Urologia Sartor O, Venugopal DR. Radiopharmaceuticals. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 255-66. ISBN 978-1-60327-831-7. RADIOFARMACOS; SAMARIO-EDTMP; CLORETO DE ESTRONCIO; RADIO; FOSFORO; PALIACAO; CANCER DE PROSTATA; METASTASES OSSEAS; TERAPIA OSSO-ALVO |
| 46/237 | US=3 / Radioterapia Wheeler DL, Hoang T, Harari PM. Contributions of targeted agents. In: Harari PM, Connor NP, Grau C. Functional preservation and quality of life in head and neck radiotherapy. New York: Springer, 2009. p. 215-23. (Medical radiology/Radiation oncology) ISBN 978-3-540-73231-0. AGENTES ALVO; CABECA E PESCOCO; CARCINOMA DE CELULAS ESCAMOSAS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); BEVACIZUMABE; TOXICIDADE; QUALIDADE DE VIDA |
| 47/237 | US=4 / Estatística Silverman D. A relevância da pesquisa qualitativa. In: ___. Interpretação de dados qualitativos: métodos para análise de entrevistas, textos e interações. 3ª ed. Porto Alegre: Artmed, 2009. p. 311-34. ISBN 85-3631697-0. |
| 48/237 | US=4 / Pediatria Patino-Garcia A, Zalacain-Diez M, Lecanda F. Molecular biology of pediatric bone sarcomas. In: Cañadell J, San-Julian M. Pediatric bone sarcomas: epiphysiolysis before excision. New York: Springer, 2009. p. 19-32. ISBN 978-1848-8213-09. SARCOMAS OSSEOS PEDIATRICOS; BIOLOGIA MOLECULAR; OSTEOSARCOMA; ANGIOGENESE; METALOPROTEINASE MATRIZ; GLICOPROTEINA P; CONTROLE DO CICLO CELULAR; TP53; RB1; FATORES DE CRESCIMENTO; ALTERACOES CROMOSSOMICAS; SARCOMA DE EDWING; ONCOPROTEINA EWS/FLI-1; GENES-ALVO |
| 49/237 | US=6 / Ortopedia Grubbs SS, Schneider CJ. Therapeutic approaches to metastatic bone cancer II: targeted and non-targeted systemic agents. In: Bronner F, Farac-Carson MC. Bone and cancer. New York: Springer-Verlag, 2009. p. 219-27. (Topics in bone biology) ISBN 978-1-84882-018-0. CANCER METASTATICO DO OSSO II; AGENTES SISTEMICOS ALVO; AGENTES SISTEMICOS NAO-ALVO; CARCINOMA DE CELULAS RENAIS; CANCER DE TIREOIDE; CANCER DE PROSTATA; CANCER DE MAMA; CANCER DE PULMAO; RADIOFARMACOS |
| 50/237 | US=11 / Gastro Masuzaki R, Omata M. HCC screening and surveillance. In: Al Knawy B, Reddy R, Bolondi L. Hepatocellular carcinoma: a practical approach. New York: Informa Healthcare, 2009. p. 26-35. ISBN 978-0415748080-2. CARCINOMA HEPATOCELULAR; TRIAGEM; VIGILANCIA; POPULACAO-ALVO; METODOLOGIA DE VIGILANCIA |
| 51/237 | US=6 / Quimioterapia Airley R. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR). In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 245-8. ISBN 978-0-470-09254-5. CHECKPOINT; PROTEINAS QUINASES; MTOR; ALVO DA RAPAMICINA EM MAMIFEROS; ATIVACAO DE MTOR; ANTICANCERIGENOS ALVO MTOR |
| 52/237 | US=22 / Urologia Jonasch E, Walker CL. EGFR and HER2: relevance in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 287-303. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; ERBB; TERAPIA-ALVO; RESISTENCIA; SINALIZACAO |
| 53/237 | US=27 / Clin/Médica Newman TB, McCulloch CE. Interpretação estatística dos dados. In: Goldman L, Ausiello D, editors. Cecil medicina. 23ª ed. Rio de Janeiro: Elsevier, 2009. p. 44-52. ISBN 85-3523677-4. |
| 54/237 | US=33 / Câncer Cheng L, Zbang S, Davidson DD, Montironi R, Lopez-Beltran A. Implications of cancer stem cells for cancer therapy. In: Bagley RG, Teicher BA. Stem cells and cancer. New York: Humana Press, 2009. p. 255-62. ISBN 978-1-60327-932-1. CELULAS-TRONCO DO CANCER; VIA DE SEGMENTACAO; TERAPIA-ALVO; MEDICINA PERSONALIZADA; CELULA-TRONCO MESENQUIMAL; BIOLOGIA ESTROMAL |
| 55/237 | US=33 / Câncer Mimeault M, Batra SK. Critical roles of tumorigenic and migrating cancer stem/progenitor cells in cancer progression and their therapeutic implications. In: Bagley RG, Teicher BA. Stem cells and cancer. New York: Humana Press, 2009. p. 287-308. ISBN 978-1-60327-932-1. TRONCO DO CANCER; CELULAS PROGENITORAS; MICROAMBIENTE ESTROMAL; TRANSICAO EPITELIAL MESENQUIMAL; CRESCIMENTO DO TUMOR; TUMORIGENICOS; CANCER MIGRATORIAS ESTAMINAIS; INVASAO; METASTASE; TERAPIAS COM ALVO; PROGENITORAS DE CELULAS; PROGRESSAO DO CANCER |
| 56/237 | US=44 / Biol/Mol Stewart FM, Stewart JA. Diagnosis and treatment of malignant diseases. In: Pardee AB, Stein GS, editors. The biology and treatment of cancer: understanding cancer. New Jersey: John Wiley & Sons, 2009. p. 57-81. ISBN 978-0-470-00958-1. DOENCAS MALIGNAS. DIAGNOSTICO; DOENCAS MALIGNAS. TRATAMENTO; CIRURGIA ROBOTICA; TERAPIA DE RADIACAO; PROTON TERAPIA; TERAPIA MEDICAMENTOSA; TERAPIA-ALVO; CUIDADOS PALIATIVOS; MEDICINA INTEGRATIVA |
| 57/237 | US=44 / Biol/Mol Komm BS. The development of drugs: current concepts and issues. In: Pardee AB, Stein GS, editors. The biology and treatment of cancer: understanding cancer. New Jersey: John Wiley & Sons, 2009. p. 183-92. ISBN 978-0-470-00958-1. DESENVOLVIMENTO DE DROGAS; OBSTACULOS NAS FASES INICIAIS; IDENTIFICACAO DO ALVO |
| 58/237 | US=44 / Biol/Mol O'Hare T, Eide CA. A new generation of drugs in cancer treatment: molecular targeted therapies. In: Pardee AB, Stein GS, editors. The biology and treatment of cancer: understanding cancer. New Jersey: John Wiley & Sons, 2009. p. 193-221. ISBN 978-0-470-00958-1. DROGAS NO TRATAMENTO DO CANCER; TERAPIA ALVO MOLECULAR; CANCER DE MAMA; EGFR EM NAO-PEQUENAS CELULAS DE CANCER DE PULMAO; MUTACAO NO MELANOMA; SINDROMES MIELODISPLASICAS |
| 59/237 | US=50 / Câncer Berz D, McCormack E, Mega A, Wanebo HJ. Targeting signaling pathways in cancer therapy. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 309-26. ISBN 978-1-60327-086-1. EGFR; RECEPTOR DO FATOR DE CRESCIMENTO EPITELIAL; INIBIDORES DA QUINASE DE TIROSINA; MOLECULAS PEQUENAS; SOLIDAS MALIGNAS DE TUMORES; TERAPIA-ALVO; PREDITORES DE RESPOSTA; CANCER DE MAMA; CARCINOMA HEPATOCELULAR; CANCER DE PULMAO; CANCER DE COLON |
| 60/237 | US=50 / Câncer Rugo HS, Lin AYJ. Targeted therapy for breast cancer: a focus on HER2/neu and antiangiogenic therapy. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 497-509. ISBN 978-1-60327-086-1. TERAPIA-ALVO PARA CANCER DE MAMA; HER2/NEU E TERAPIA ANTIANGIOGENICA; CANCER DE MAMA METASTATICO; HER2/NEU; TRASTUZUMAB; LAPATINIB; BEVACIZUMAB; SUNITINIB; ANTIANGIOGENICO; TERAPIA-ALVO |